Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines

다국어 초록 (Multilingual Abstract)

Purpose Current chemotherapeutics for treating locally advanced or metastatic soft tissue sarcomas (STS) are limited. Accordingly, the present in vitro study was conducted to evaluate the effects of treatment of STS cells with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) applied as a single agent or in combination with a proteasome inhibitor, MG132.
Materials and Methods Sensitivity to TRAIL and activity of TRAIL-induced apoptotic pathways were analyzed in four STS cell lines: HTB-82 (rhabdomyosarcoma), HT-1080 (fibrosarcoma), HTB-93 (synovial sarcoma), and HTB-94 (chondrosarcoma). Reduction of the dye dimethylthiazolyl 2,5diphenyltetrazolium bromide (MTT) was used to evaluate cytotoxic activity; western blots were used to evaluate TRAIL-induced apoptosis.
Results TRAIL induced apoptosis in HTB-93 cells, but had little effect in HTB-82, HT-1080, or HTB-94cells. Expression of TRAIL receptor-1 and -2 did not correlate with sensitivity to TRAIL. Coincubation of cells with TRAIL and a proteasome inhibitor, MG132, augmented the apoptotic effect of TRAIL in both TRAIL-sensitive and TRAIL-resistant cells. This effect was due to upregulation of TRAIL receptors and members of the pro-apoptotic BCL-2 family by MG132.
Conclusion These data show that combining TRAIL with MG132 enhances apoptosis and overcomes TRAIL resistance. This restoration of TRAIL sensitivity occurs through an increase in the expression of death receptor 5 and of pro-apoptotic BCL-2 family members such as BAX.

참고문헌 (Reference)

1 Pan G, "The receptor for the cytotoxic ligand TRAIL" 276 : 111-113, 1997

2 Adams J, "The proteasome: a suitable antineoplastic target" 4 : 349-360, 2004

3 Johnson TR, "The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9- negative or Bcl-xL overexpressing cells" 22 : 4953-4963, 2003

4 Ashkenazi A, "Targeting death and decoy receptors of the tumour-necrosis factor superfamily" 2 : 420-430, 2002

5 Walczak H, "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" 16 : 5386-5397, 1997

6 Voortman J, "TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib" 6 : 2103-2112, 2007

7 Chen JJ, "Proteasome inhibitors enhance TRAILinduced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation" 180 : 8030-8039, 2008

8 Jin Z, "Overview of cell death signaling pathways" 4 : 139-163, 2005

9 Emery JG, "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL" 273 : 14363-14367, 1998

10 Khanbolooki S, "Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells" 5 : 2251-2260, 2006

11 Pawlowski JE, "NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL)" 20 : 4243-4255, 2000

12 Clarkson P, "Management of soft tissue sarcomas of the extremities" 4 : 237-246, 2004

13 Ogasawara J, "Lethal effect of the anti-Fas antibody in mice" 364 : 806-809, 1993

14 Pitti RM, "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family" 271 : 12687-12690, 1996

15 Hao C, "Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells" 61 : 1162-1170, 2001

16 Lienard D, "High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma" 10 : 52-60, 1992

17 Sayers TJ, "Combining proteasome inhibition with TNF-related apoptosisinducing ligand (Apo2L/TRAIL) for cancer therapy" 55 : 76-84, 2006

18 Degli-Esposti MA, "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family" 186 : 1165-1170, 1997

19 Li H, "Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis" 94 : 491-501, 1998

20 Luo X, "Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors" 94 : 481-490, 1998

21 Antman K, "An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas" 11 : 1276-1285, 1993

22 Marsters SA, "A novel receptor for Apo2L/TRAIL contains a truncated death domain" 7 : 1003-1006, 1997